Latest Headlines

  1. Inivata’s Liquid Biopsy Technology Included In Unique £10M Research Collaboration For Early Detection Of Lung Cancer 12/24/2020

    Inivata, a leader in liquid biopsy, today announces its participation in a major research collaboration to investigate integrated diagnostics for the early detection of lung cancer with the aim of increasing survival rates, alongside improving the efficiency of testing in people at high risk of cancer in the NHS. The program’s goal is to streamline the process of detecting cancers and reduce the NHS resources that are needed in order to find each new case

  2. Quidel Receives Emergency Use Authorization For Moderately Complex Solana SARS Molecular Test For COVID-19 Diagnosis 12/23/2020

    Quidel Corporation (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its Solana® SARS-CoV-2 Assay, an isothermal Reverse Transcriptase - Helicase-Dependent Amplification (RT-HDA) assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal (NP) and nasal (NS) swab specimens in viral transport

  3. Simply Spit: MOgene Launches Their Saliva Based SARS-CoV-2 Test For COVID-19 With A Comprehensive Testing & Screening Program For Employers And Their Companies 12/23/2020

    MOgene, a leading provider of genomics and molecular services worldwide, announced today a new, comprehensive saliva-based COVID-19 testing service to employers for the safety of their employees.

  4. Co-Diagnostics Designs Test To Detect Mutations For New Coronavirus Strain Using CoPrimer™ Platform 12/22/2020

    Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed principal design work for a PCR test that would allow researchers to identify certain mutations in a newly detected variant of SARS-CoV-2 known as VUI 202012/01

  5. Concert Genetics Unveils End-To-End Genetic Testing Management Program For Health Plans 12/22/2020

    Concert Genetics today unveiled the Concert Genetics Benefit Program, an end-to-end genetic testing management solution that enables health plans to provide members with access to high-quality, clinically appropriate genetic testing while improving payment integrity and reducing manual work

  6. ProPath Adds New Test For The Detection Of Synovial Sarcoma 12/21/2020

    ProPath’s Immunohistochemistry (IHC) laboratory has obtained a significant new addition to its library of over 300 antibody tests. Cary J. Buresh, M.D., ProPath’s Director of Immunohistochemistry, stated, “I am happy to announce the addition of SS18-SSX to our antibody library

  7. Q2 Solutions, An IQVIA And Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies To Market immunoSEQ Assay, The Leading Quantitative Large-Scale Immunosequencing Solution 12/21/2020

    Q2 Solutions, a leading global clinical trial laboratory services organization, resulting from an IQVIA and Quest Diagnostics joint venture, today announced a partnership with Adaptive Biotechnologies, a pioneer and leader in immune-driven medicine

  8. Beroni Group’s SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) Received CE Certification 12/21/2020

    Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an Australia-based diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases today announced that it has received notification from its European Authorized Representative, CMC Medical Devices & Drugs SL, that its newly developed SARS-CoV-2 Antigen Test Kit (Colloidal Gold Method) complies with the applicable essential requirements of the council directive 98/79/EEC in vitro diagnostics as amended

  9. U.S. Patent Office Upholds Validity Of Natera's Early Priority Date '592 cfDNA Patent 12/19/2020

    Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, is pleased that the United States Patent Office granted Natera a significant win when it denied a patentability challenge from a multi-national sequencing company against Natera's U.S. Patent No. 8,682,592 ('592 Patent) upholding all claims. Natera's '592 Patent claims early and significant innovations directed to generating genetic data from limited quantities of DNA, including cfDNA

  10. World's Largest Manufacturer Of Rapid Antigen Tests Acquires California-Based BIOLAB 12/19/2020

    Innova Medical Group, Inc. (IMG), the world's largest manufacturer of rapid antigen test kits, acquired California-based Biological Laboratory Inc. (BIOLAB), further strengthening IMG's in-house diagnostic testing and research and development capability in the U.S.